Educational guide
5-Amino-1MQ (10 mg Vial) Dosage Protocol
5-Amino-1MQ (10 mg Vial) Dosage Protocol 5-Amino-1MQ Dosage Chart 5-Amino-1MQ is dosed at 2.5 mg–5 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 5 mg/mL. This information is for
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
5-Amino-1MQ (10 mg Vial) Dosage Protocol
5-Amino-1MQ Dosage Chart
5-Amino-1MQ is dosed at 2.5 mg–5 mg daily via subcutaneous injection in educational protocols. A 10 mg vial reconstituted with bacteriostatic water yields about 5 mg/mL. This information is for research and educational use only.
Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL concentration.
Typical daily range: 2.5–5 mg once or twice daily (subcutaneous).
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg (0.05 mg) on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks[4].
5-Amino-1MQ dosage protocols center on this selective, cell-permeable NNMT (Nicotinamide N-methyltransferase) inhibitor studied for its potential to support fat metabolism, preserve lean muscle mass, and elevate intracellular NAD+ levels[1][2]. By blocking NNMT, 5-Amino-1MQ may help restore cellular energy balance and activate SIRT1 pathways associated with metabolic efficiency[3]. This educational protocol presents a subcutaneous injection approach to maximize bioavailability from the 10 mg vial format.
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read 5-Amino-1MQ Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
Subcutaneous Protocol (2 mL = 5 mg/mL)
Days 1–2 (Tolerance)
2.5 mg (2500 mcg)
50 units (0.50 mL)
Days 3+ (Standard)
5 mg (5000 mcg)
100 units (1.00 mL)
Alternative BID
2.5 mg twice daily
50 units (0.50 mL) × 2
Frequency: Inject once or twice daily subcutaneously. Due to the compound’s plasma half-life of approximately 3.8–6.9 hours[5], twice-daily (BID) dosing may provide more sustained NNMT inhibition. A single 10 mg vial provides 2–4 days of material at these doses.
Reconstitution Steps
Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved—solution should be clear (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 2–4 weeks.
Supplies Needed
Plan based on protocol duration using the 10 mg vial format at 5 mg/day.
1 week (5 mg/day = 35 mg total) → 4 vials
2 weeks (5 mg/day = 70 mg total) → 7 vials
4 weeks (5 mg/day = 140 mg total) → 14 vials
1 week (once daily): 7 syringes
2 weeks (once daily): 14 syringes
4 weeks (once daily): 28 syringes
1 week (4 vials × 2.0 mL = 8 mL) → 1 × 10 mL bottle
2 weeks (7 vials × 2.0 mL = 14 mL) → 2 × 10 mL bottles
4 weeks (14 vials × 2.0 mL = 28 mL) → 3 × 10 mL bottles
1 week (once daily): 14 swabs
2 weeks (once daily): 28 swabs
4 weeks (once daily): 56 swabs → recommend 1 × 100-count box
Protocol Overview
Concise summary of the subcutaneous regimen.
Goal: Support metabolic efficiency through NNMT inhibition, potentially enhancing fat oxidation and NAD+ levels[1][2].
Schedule: Daily subcutaneous injections; each 10 mg vial provides 2–4 days of material.
Dose Range: 2.5–5 mg once or twice daily.
Reconstitution: 2.0 mL per 10 mg vial (5 mg/mL) for accurate measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F).
Dosing Protocol
Suggested approach for the 10 mg vial format.
Start: 2.5 mg once daily to assess tolerance.
Target: 5 mg once daily or 2.5 mg twice daily (BID).
Frequency: Once or twice per day (subcutaneous).
Vial Duration: Single 10 mg vial lasts 2–4 days at standard doses.
Timing: Morning administration preferred; BID dosing may be split AM/PM.
Storage Instructions
Proper storage preserves compound stability.
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable up to 24 months[4].
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 2–4 weeks.
Allow vials to reach room temperature before reconstitution to prevent condensation and pressure issues.
Do not refreeze reconstituted solution.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each administration; dispose in a sharps container[6].
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation[7].
Inject slowly; a mild stinging sensation may occur due to the quinolinium structure.
Document daily dose and site rotation to maintain consistency.
The 10 mg vial format requires multiple vials for extended protocols; plan supplies accordingly.
How This Works
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule that selectively inhibits Nicotinamide N-methyltransferase (NNMT)[1]. NNMT is a cytosolic enzyme that methylates nicotinamide (vitamin B3) using S-adenosylmethionine (SAM) as a methyl donor. In states of obesity and metabolic dysfunction, NNMT is often overexpressed in adipose tissue, depleting nicotinamide and reducing NAD+ availability[2].
By inhibiting NNMT, 5-Amino-1MQ may spare nicotinamide for NAD+ synthesis via the salvage pathway, thereby activating SIRT1 (Sirtuin 1) pathways associated with mitochondrial biogenesis, fat oxidation, and metabolic flexibility[3]. Preclinical studies indicate that NNMT knockdown or inhibition can protect against diet-induced weight gain and improve metabolic parameters without reducing food intake[8][9].
Potential Benefits & Side Effects
Observations from preclinical and early research literature.
May support reductions in fat mass while preserving lean muscle in animal models[8][9].
Associated with elevated NAD+ levels and SIRT1 activation in preclinical studies[2][3].
Enhanced grip strength observed in aged mice when combined with exercise[10].
Generally well tolerated; occasional reports of mild headache, transient jitteriness, or injection-site reactions.
Long-term human safety data not established; this compound remains investigational.
Lifestyle Factors
Complementary strategies for best outcomes.
Pair with a balanced, protein-forward diet tailored to energy needs.
Combine resistance training and aerobic activity—preclinical data suggest synergy with exercise[10].
Prioritize sleep and stress management to support metabolic adaptation.
Consider complementary NAD+ precursors (NMN/NR) per emerging stack protocols[11].
Injection Technique
General subcutaneous guidance from clinical best-practice resources[6].
Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[7].
Slow injection may minimize any stinging sensation associated with the compound.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
Nature Medicine (2014) — Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity View Source
PMC (2024) — Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunctions View Source
Frontiers in Pharmacology (2024) — NNMT: a novel therapeutic target for metabolic syndrome View Source
Creative Peptides — Peptide stability and storage guidelines for lyophilized compounds View Source
PubMed (2021) — LC-MS/MS assay for 5-amino-1-methylquinolinium: pharmacokinetic and oral bioavailability study View Source
PMC — Subcutaneous drug injection review: pharmacologic considerations View Source
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source
ResearchGate (2021) — Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese mice View Source
PMC (2022) — Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice View Source
Scientific Reports / NMN.com — Role of NNMT inhibition in muscle strength: enhanced grip strength with exercise View Source
Swolverine — 5-Amino-1MQ mechanism, benefits, stacking and cycling guide View Source
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) View Source
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections View Source
Additional Research and Background
These sources provide related context and are not presented as support for a specific statement above.
Journal of Medicinal Chemistry (ACS) — Bisubstrate inhibitors of NNMT with enhanced activity View Source
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
5-Amino-1MQ Peptide: Benefits, Uses, Side Effects, Dosage, and Research
Other vial-size protocols
5-Amino-1MQ (50 mg Vial) Dosage Protocol
Practical guides
Single Peptide Dosages
Peptide Dosage & Reconstitution Calculator
How to Reconstitute Peptides
Syringe & Measurement Guide
Peptide Storage Guide
Peptide Dosage Chart